Interleukin-6 deficiency fails to prevent chronic rejection after aortic allografts in apolipoprotein E-deficient mice

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
H Yacoub-YoussefM Thomsen

Abstract

Chronic vascular rejection (CVR) is characterized by an intimal thickening in the arteries of allografts due to immunoinflammatory reactions and smooth muscle cell proliferation. Interleukin 6 (IL-6) levels are increased in patients with graft rejection, however the role of IL-6 in CVR is not known. We investigated if IL-6 deficiency in the recipient could prevent CVR after an aortic allograft. Donor aortas from wild-type DBA/2 mice were transplanted into C57BL/6 recipients, either wild-type mice or mice deficient for IL-6 (IL-6(-/-)), apolipoprotein E (ApoE(-/-)), or both (IL-6(-/-)ApoE(-/-)). Alloantibody titers were determined at Day 30, 60, or 90 after grafting. The grafts were examined for CVR lesions by morphometry and immunohistology. All recipient allografts displayed lesions typical for CVR. The lesions were larger in IL-6-deficient strains, and significantly so in IL-6(-/-)ApoE(-/-) recipients. Early immunoglobulin (Ig) G1 alloantibody deposits were observed in the grafts of ApoE-deficient strains and late IgG2a deposits in the grafts of IL-6-deficient strains. A rapid and sustained type 1 helper T cell (Th1; IgG2a) alloresponse in IL-6(-/-) mice, and a strong type 2 helper T cell (Th2; IgG1) response in ApoE(-/-) mic...Continue Reading

References

Sep 1, 1991·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·D E HricikJ A Schulak
Sep 15, 1995·Transplantation·D PlissonnierJ B Michel
Jan 28, 1994·Cell·W E Paul, R A Seder
Apr 30, 1996·Proceedings of the National Academy of Sciences of the United States of America·C ShiE Haber
Sep 18, 1997·Immunology Today·H TilgJ W Mier
Nov 24, 1999·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·C DambrinM Thomsen
Aug 10, 2000·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·C G Orosz
Aug 10, 2000·The American Journal of Pathology·H DietrichQ Xu
Sep 12, 2000·The American Journal of Pathology·J F LégaréG Hirsch
Mar 27, 2001·Transplantation Proceedings·M BoratyńskaK Polak
May 5, 2001·Immunity·P Libby, J S Pober
Jul 31, 2001·Transplantation·J L TangA W Thomson
Nov 15, 2002·Molecular Immunology·Sean Diehl, Mercedes Rincón
Aug 29, 2003·The New England Journal of Medicine·Robin K Avery
Oct 28, 2003·Transplantation·Mahmoud SadeghiGerhard Opelz
Feb 21, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Emile AndriambelosonMarc Bigaud
Apr 20, 2004·Japanese Heart Journal·Tsugiyasu Kanda, Takashi Takahashi
Mar 18, 2005·Annual Review of Immunology·Tadamitsu Kishimoto
Apr 9, 2005·Transplant Immunology·A PawlikB Gawronska-Szklarz
May 18, 2005·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Cameron G DensemNicholas H Brooks
Jul 9, 2005·Transplantation·Alfonso M Cueto-ManzanoJosefina Alberú
Sep 24, 2005·Circulation Research·Kamilah AliDaniel J Rader
Sep 27, 2005·Transplantation Proceedings·H Yacoub-YoussefM Thomsen
Dec 21, 2005·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Satoru Kitagawa-SakakidaHikaru Matsuda
Apr 14, 2007·Circulation Research·Richard N Mitchell, Peter Libby

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.